Journal
LEUKEMIA
Volume 22, Issue 12, Pages 2240-2246Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2008.263
Keywords
myeloma; IL-29; IFN-lambda
Categories
Funding
- National Institutes of Health [CA062242]
- ZymoGenetics Inc.
- Merck Serono International SA, an affiliate of Merck KGaA, Darmstadt, Germany
Ask authors/readers for more resources
Multiple myeloma (MM) is a progressive disease that results from dysregulated proliferation of plasma cells. Although, causative factors such as genetic events and altered expression of anti-apoptotic factors have been described in a number of patients, the mechanistic details that drive myeloma development and continued growth of malignant cells remain largely undefined. Numerous growth factors, including interleukin (IL)-6, Insulin-like growth factor-1 and IL-10 have been shown to promote growth of MM cells suggesting a significant role for cytokines in this disease. Interferon (IFN)-lambda 1 is a new member of the Class II cytokine family that, similar to IFN-alpha, has been shown to mediate viral immunity. In light of data supporting a role for cytokines in myeloma, we investigated the significance of IFN-lambda 1 on myeloma cell biology. Our studies show for the first time that myeloma cells bind to soluble IFN-lambda 1, and that IFN-lambda 1 induces myeloma cell growth and protects against dexamethasone-induced cell death. Our data also show that IFN-lambda 1 induces phosphorylation of STAT1, STAT3 and Erk. Taken together, our results suggest that IFN-lambda 1 may regulate myeloma cell biology and could prove to be therapeutically important.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available